A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019

[1]  S. Oğuz,et al.  Endocrine Disorders and COVID-19. , 2022, Annual review of medicine.

[2]  Athanasios N. Papadopoulos,et al.  Obesity and Infection: What Have We Learned From the COVID-19 Pandemic , 2022, Frontiers in Nutrition.

[3]  B. Haagmans,et al.  SARS-CoV-2 pathogenesis , 2022, Nature Reviews Microbiology.

[4]  Leiliang Zhang,et al.  Palmitoylation of SARS‐CoV‐2 S protein is critical for S‐mediated syncytia formation and virus entry , 2021, Journal of medical virology.

[5]  Dennis Andersson,et al.  Ensuring trust in COVID-19 data , 2021, Medicine.

[6]  Zhuanchang Wu,et al.  Palmitoylation of SARS-CoV-2 S protein is essential for viral infectivity , 2021, Signal Transduction and Targeted Therapy.

[7]  G. Ippolito,et al.  Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis , 2021, Cell Death & Disease.

[8]  I. Adcock,et al.  COVID-19: Molecular and Cellular Response , 2021, Frontiers in Cellular and Infection Microbiology.

[9]  F. Khanim,et al.  The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models , 2021, bioRxiv.

[10]  Shijian Zhang,et al.  Spike Glycoprotein and Host Cell Determinants of SARS-CoV-2 Entry and Cytopathic Effects , 2020, Journal of Virology.

[11]  Matan Hofree,et al.  The SARS-CoV-2 Transcriptional Metabolic Signature in Lung Epithelium , 2020 .

[12]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[13]  Fang Lei,et al.  Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.

[14]  B. Boehm,et al.  Endocrine and metabolic link to coronavirus infection , 2020, Nature Reviews Endocrinology.

[15]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[16]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[17]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[18]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[19]  J. Chan,et al.  Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication , 2019, Viruses.

[20]  M. Fay,et al.  Confidence intervals of the Mann‐Whitney parameter that are compatible with the Wilcoxon‐Mann‐Whitney test , 2018, Statistics in medicine.

[21]  K. Anstrom,et al.  Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. , 2017, Journal of the American College of Cardiology.

[22]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[23]  Hongfei Liu,et al.  PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway , 2016, Journal of Molecular Neuroscience.

[24]  A. Gorbalenya,et al.  Modulation of the Host Lipid Landscape to Promote RNA Virus Replication: The Picornavirus Encephalomyocarditis Virus Converges on the Pathway Used by Hepatitis C Virus , 2015, PLoS pathogens.

[25]  W. Seeger,et al.  PPAR-α activation reduced LPS-induced inflammation in alveolar epithelial cells , 2015, Experimental lung research.

[26]  U. Ladabaum,et al.  Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988 to 2010. , 2014, The American journal of medicine.

[27]  D. Hilleman,et al.  A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations , 2013, Cardiology research.

[28]  G. Felker,et al.  A global rank end point for clinical trials in acute heart failure. , 2010, Circulation. Heart failure.

[29]  W. Seeger,et al.  Peroxisome proliferator-activated receptor-α reduces inflammation and vascular leakage in a murine model of acute lung injury , 2008, European Respiratory Journal.

[30]  A. Su,et al.  The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[31]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[32]  David Brink,et al.  : A Review of the , 2018 .

[33]  Karen Shashok,et al.  BMC Medical Research Methodology BioMed Central Debate Conducting a meta-ethnography of qualitative literature: Lessons learnt , 2008 .

[34]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[35]  P. Elteren.  On the combination of independent two-sample tests of wilcoxon : Corrected version , 1959 .